<DOC>
	<DOCNO>NCT01342159</DOCNO>
	<brief_summary>One frequent complication diabetic retinopathy diabetic macular edema . Recently , intravitreal bevacizumab intravitreal triamcinolone popular therapeutic modality . However , long term effect intravitreal bevacizumab intravitreal triamcinolone visual acuity macular thickness compare , purpose present study compare treatment effect</brief_summary>
	<brief_title>Intravitreal Bevacizumab Triamcinolone Diabetic Macular Edema</brief_title>
	<detailed_description>Randomization intravitreal bevacizumab , intravitreal triamcinolone , intravitreal bevacizumab triamcinolone eye diabetic macular edema</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Diabetic macular edema ( central macular thickness great 300 mm optical coherence tomography ) history glaucoma ocular hypertension ( define intraocular pressure high 22 mmHg ) ocular condition ( diabetes ) , opinion investigator , might affect macular oedema alter visual acuity course study ( e.g . retinal vein occlusion , uveitis ocular inflammatory disease , neovascular glaucoma , IrvineGass Syndrome , etc . ) systemic corticosteroid therapy history thromboembolic event ( include myocardial infarction cerebral vascular accident ) major surgery within prior 6 month plan within next 28 day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>bevacizumab , diabetic macular edema , triamcinolone</keyword>
</DOC>